Rockville, MD – According to filings with the U.S. Securities and Exchange Commission, Silvec Biologics is raising $3,000,000.00 in new funding. Sources indicate as part of senior management Partner, Rafael Simon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Silvec Biologics

Silvec is developing the first non-GMO process to inoculate against tree, vine, and bush diseases in both seedlings and mature trees. The technology is based on a new type of infectious RNA discovered by Silvec’s founder. We believe this technology represents a comparable breakthrough for trees as the invention of vaccines and antibiotics have had for humans.

To learn more about Silvec Biologics, visit http://silvecbiologics.com/

Contact:
Rafael Simon, Partner
310-463-6625
https://www.linkedin.com/in/rafael-simon-832b4676/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved